
    
      Up to 5 dose cohorts will be studied. Participants will be assigned to a dose cohort in the
      order they enter the study.

        -  1 mg/kg of NIVOLUMAB + peptide vaccine (1 mg/kg cohort), then

        -  3 mg/kg of NIVOLUMAB + peptide vaccine (3 mg/kg cohort), then

        -  10 mg/kg of NIVOLUMAB + peptide vaccine (10 mg/kg cohort), then

        -  1 mg/kg NIVOLUMAB + ipilimumab 3 mg/kg combination cohort

        -  3 mg/kg NIVOLUMAB + ipilimumab 1 mg/kg combination cohort
    
  